Lurbinectedin联合多柔比星治疗复发性小细胞肺癌的I期研究
该I期研究确定多柔比星50 mg/m2与Lurbinectedin 4.0 mg固定剂量第1天每3周给药的推荐剂量,并在27例复发性小细胞肺癌中观察到抗肿瘤活性,二线敏感性疾病缓解率91.7%,耐药性疾病33.3%,耐受性可控,已推进至III期试验。
要点
- 推荐剂量为多柔比星50 mg/m2联合Lurbinectedin 4.0 mg固定剂量,第1天每3周给药。
- 复发性小细胞肺癌二线敏感性疾病缓解率91.7%,中位无进展生存期5.8个月。
- 复发性小细胞肺癌二线耐药性疾病缓解率33.3%,中位无进展生存期3.5个月。
核心结论
- 多柔比星50 mg/m2与Lurbinectedin 4.0 mg固定剂量第1天每3周给药在复发性小细胞肺癌中显示出显著活性,主要见于二线治疗,耐受性可控,已推动该联合方案在正在进行的III期试验中进一步评估。
研究设计与样本
- I期试验采用标准剂量递增设计,并在推荐剂量下扩展,确定多柔比星(静脉推注)与Lurbinectedin(1小时静脉输注)第1天每3周给药的推荐剂量。
- 27例复发性小细胞肺癌患者纳入分析,其中12例为敏感性疾病(无铂间隔≥90天),15例为耐药性疾病(无铂间隔<90天)。
主要发现
- 复发性小细胞肺癌中完全缓解2例(8%),部分缓解13例(50%),多数在推荐剂量下发生。
- 二线治疗敏感性疾病缓解率91.7%,中位无进展生存期5.8个月;耐药性疾病缓解率33.3%,中位无进展生存期3.5个月。
- 三线治疗缓解率20.0%,中位无进展生存期1.2个月,均为耐药性疾病。
- 推荐剂量下治疗耐受性可控,主要毒性为短暂可逆的骨髓抑制(包括中性粒细胞减少、血小板减少和发热性中性粒细胞减少),通过剂量调整和集落刺激因子管理。
- 常见不良事件包括乏力(79%)、恶心/呕吐(58%)、食欲下降(53%)、黏膜炎(53%)、脱发(42%)、腹泻/便秘(42%)、无症状肌酐升高(68%)和转氨酶升高(丙氨酸氨基转移酶42%;天冬氨酸氨基转移酶32%),大多为轻至中度。
关键数值与推荐
- 推荐剂量:多柔比星50 mg/m2联合Lurbinectedin 4.0 mg固定剂量,第1天每3周给药。
- 敏感性疾病定义:无铂间隔≥90天;耐药性疾病定义:无铂间隔<90天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial determined the recommended dose (RD) of doxorubicin (bolus) and PM01183 (1-h intravenous infusion) on day 1 every 3 weeks (q3wk), and obtained preliminary evidence of antitumor activity for this combination in small-cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with advanced solid tumors received doxorubicin and PM01183 following a standard dose escalation design and expansion at the RD. Twenty-seven patients had relapsed SCLC: 12 with sensitive disease (platinum-free interval ≥90 days) and 15 with resistant disease (platinum-free interval <90 days). RESULTS: Doxorubicin 50 mg/m2 and PM01183 4.0 mg flat dose was the RD. In relapsed SCLC, treatment tolerance at the RD was manageable. Transient and reversible myelosuppression (including neutropenia, thrombocytopenia, and febrile neutropenia) was the main toxicity, managed with dose adjustment and colony-stimulating factors. Fatigue (79%), nausea/vomiting (58%), decreased appetite (53%), mucositis (53%), alopecia (42%), diarrhea/constipation (42%), and asymptomatic creatinine (68%) and transaminase increases (alanine aminotransferase 42%; aspartate aminotransferase 32%) were common, and mostly mild or moderate. Complete (n = 2, 8%) and partial response (n = 13, 50%) occurred in relapsed SCLC, mostly at the RD. Response rates at second line were 91.7% in sensitive disease [median progression-free survival (PFS)=5.8 months] and 33.3% in resistant disease (median PFS = 3.5 months). At third line, response rate was 20.0% (median PFS = 1.2 months), all in resistant disease. CONCLUSION: Doxorubicin 50 mg/m2 and PM01183 4.0 mg flat dose on day 1 q3wk has shown remarkable activity, mainly in second line, with manageable tolerance in relapsed SCLC, leading to further evaluation of this combination within an ongoing phase III trial.
引用
- Calvo E, Moreno V, Flynn M, et al. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann Oncol. 2017. PMID: 28961837. doi:10.1093/annonc/mdx357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。